Merck Animal Health announces that AROVYN™ (tulathromycin injection) is now available to veterinarians prescribing tulathromycin, which is used to control and treat bovine respiratory disease (BRD), plus treat foot rot and pinkeye. The prescription antibiotic, recently approved by the FDA, is the latest addition to the comprehensive antimicrobial portfolio and BRD solutions from Merck Animal Health.
     “AROVYN offers veterinarians and producers a new, cost-effective option for tulathromycin from an animal health company they know and trust,” said John Champagne, D.V.M., dairy technical services, Merck Animal Health.
     In beef and non-lactating dairy cattle, AROVYN is indicated for the treatment of BRD and control of respiratory disease in animals at high risk of developing BRD associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis. It also is approved for treatment of pinkeye or infectious bovine keratoconjunctivitis (IBK) associated with Moraxella bovis, plus treatment of foot rot associated with Fusobacterium necrophorum and Porphyromonas levii. In suckling calves, dairy calves and veal calves, AROVYN is indicated for treatment of BRD associated with M. haemolytica, P. multocida, H. somni and M. bovis.
     “AROVYN is backed by Merck Animal Health’s technical service and sales team with extensive expertise in managing BRD, cattle health and well-being,” explained Dr. Champagne. “The Merck Animal Health dairy portfolio offers multiple options to help producers manage BRD in calves, including a first-of-its-kind intranasal vaccine, BOVILIS® NASALGEN® 3-PMH.”